- Home
- CR vs ROIV Comparison
CR vs ROIV Comparison
Compare CR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | ROIV |
|---|---|---|
| Founded | 1855 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CR | ROIV |
|---|---|---|
| Price | $191.93 | $21.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $223.60 | $21.94 |
| AVG Volume (30 Days) | 343.9K | ★ 6.7M |
| Earning Date | 01-26-2026 | 11-10-2025 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | ★ 37.96 | N/A |
| EPS | ★ 6.25 | N/A |
| Revenue | ★ $2,268,100,000.00 | $20,329,000.00 |
| Revenue This Year | $10.78 | N/A |
| Revenue Next Year | $13.09 | $376.94 |
| P/E Ratio | $30.68 | ★ N/A |
| Revenue Growth | ★ 19.64 | N/A |
| 52 Week Low | $127.04 | $8.73 |
| 52 Week High | $203.89 | $22.45 |
Technical Indicators
Market Signals| Indicator | CR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 60.34 | 62.44 |
| Support Level | $185.77 | $20.14 |
| Resistance Level | $194.17 | $21.48 |
| Average True Range (ATR) | 3.59 | 0.71 |
| MACD | 1.14 | 0.00 |
| Stochastic Oscillator | 81.57 | 65.96 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.